"While many of the investments presented to the group are , these investments also have the potential for a !"
ANNOVIS is a specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.
Posiphen reduces levels of amyloid precursor protein (APP), tau and α-Synuclein (aSYN), three proteins that can turn toxic and precipitate the onset of AD and PD. Posiphen inhibits APP, tau and aSYN in tissue culture cells, mice as well as in humans.